Wafik El-Deiry, Director of Legorreta Cancer Center at Brown University and Chair of the WIN Consortium in Cancer Personalized Medicine, shared on LinkedIn:
“Razelle Kurzrock, Chief Medical Officer, WIN Consortium, Professor, Medical College of Wisconsin, USA, delivers Keynote on ‘From Molecular Profiling to N-of-1 Oncology: Lessons from the iPREDICT trial paradigm’ at the 2026 WIN Symposium in Rhode Island on 10-2-2026.
Razelle Kurzrock is a world-renowned physician-scientist leader in precision medicine as well as in novel cancer therapeutics development.
She is recognized for founding, developing and chairing one of the largest Phase 1 clinical trial departments globally while at the University of Texas MD Anderson Cancer Center; the central theme of the department was a personalized medicine strategy. She led key early- or later-phase trials of 8 drugs that led to FDA approval. She is also one of the pioneering trialists of the WINTHER precision medicine international trial in five countries focusing, for the first time, on transcriptomics in addition to genomics. This trial was the signature study of the WIN consortium; published Nature Medicine, 2019.
She also developed and pioneered some of the first tumor-agnostic cancer clinical trials and is recognized as having led the way for the molecular reclassification of cancer.
During her time at the University of California San Diego Health, Dr. Kurzrock’s charge was founding and leading the Center for Personalized Cancer Therapy as well as the Experimental Therapeutics program, and she also founded a Rare Tumor Clinic focused on precision medicine. The signature study of the center was the iPREDICT study; Nature Medicine, 2019, that gave, for the first time, individualized N-of-1 matched combination therapies to patients with lethal malignancies.
This work was presented at the Nobel Symposium, Karolinska Institute, Stockholm, Sweden in September 2023.
Dr. Kurzrock also served on the Board of Directors and was elected to the Executive Committee for NCCN. She has also served as Chair of the Early Therapeutics and Rare Cancers Committee, for NCI and SWOG, one of the largest clinical trial cooperative groups in the world; in this capacity, she was a PI of the DART trial that provided dual immunotherapy for patients with rare or ultra-rare cancers; the trial open at over 1000 sites, accrued ~800 patients, resulted in multiple NCCN guideline changes and was recognized with the NCI Director’s Award of Merit.
Dr. Kurzrock’s strong record of funding is comprised of ~$125 million in lifetime funding, including ~$50 million in NIH or peer-related research support.
Ray Kurzrock is also an entrepreneur. She is co-founder of CureMatch, and on the Board of CureMetrix, CureMatch, and Xzom.
Dr. Kurzrock is the author of over 1,000 peer-reviewed articles on PubMed and holds a highly exceptional Hirsch index or h-index score of 161, with ~110,000 citations. She has been selected each year since 2019 on the Clarivate Web of Science list of most cited scientists worldwide.”
Read more articles about WIN Symposium on OncoDaily.